Department of Internal Medicine, "L. Vanvitelli" University, 80131 Naples, Italy.
Division of Cardiology, "A. Cardarelli" Hospital, Via A. Cardarelli, 6, 80131 Naples, Italy.
Medicina (Kaunas). 2024 Sep 28;60(10):1595. doi: 10.3390/medicina60101595.
Anterior myocardial infarction is a critical condition with significant implications for cardiac function and patient prognosis. Despite advancements in reperfusion therapies, optimizing recovery during the early phases of myocardial infarction remains challenging. Anterior myocardial infarction can lead to substantial long-term effects on a patient's health due to extensive damage to the heart muscle, particularly the left ventricle, impacting both quality of life and overall prognosis. Vericiguat, a soluble guanylate cyclase stimulator, has shown promise in heart failure, but its role in early anterior myocardial infarction has not yet been fully explored. By enhancing soluble guanylate cyclase activity, vericiguat may increase cyclic guanosine monophosphate production, leading to vasodilation, inhibition of platelet aggregation, and potential cardioprotective effects. Currently, treatment options for anterior myocardial infarction primarily focus on reperfusion strategies and managing complications. However, there is a critical need for adjunctive therapies that specifically target the pathophysiological changes occurring in the early phases of myocardial infarction. Vericiguat's mechanism of action offers a novel approach to improving vascular function and myocardial health, potentially contributing to innovative treatment strategies that could transform the care and prognosis of patients with anterior myocardial infarction.
前壁心肌梗死是一种严重的疾病，对心脏功能和患者预后有重大影响。尽管再灌注治疗有所进展，但优化心肌梗死早期的恢复仍然具有挑战性。前壁心肌梗死可能会对患者的健康产生重大的长期影响，因为心肌，特别是左心室，会受到广泛的损伤，这会影响生活质量和整体预后。维立西呱是一种可溶性鸟苷酸环化酶刺激剂，在心力衰竭方面显示出了潜力，但它在前壁心肌梗死早期的作用尚未得到充分探索。通过增强可溶性鸟苷酸环化酶的活性，维立西呱可能会增加环鸟苷酸单磷酸的产生，从而导致血管扩张、抑制血小板聚集以及可能的心脏保护作用。目前，前壁心肌梗死的治疗选择主要集中在再灌注策略和管理并发症上。然而，迫切需要专门针对心肌梗死早期发生的病理生理变化的辅助治疗方法。维立西呱的作用机制为改善血管功能和心肌健康提供了一种新的方法，可能为改善前壁心肌梗死患者的治疗策略提供新的途径，从而改变对这些患者的治疗和预后。
